IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3173
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.0B
Purnanand D. Sarma
Immunome, Inc. discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$IMNM Immunome Inc. | 43 | 25 | 27 | 84 | - | - | -71.8% | -63.3% | - | -1473.1% | -1374.2% | -100.0% | 0.0% | 13.0x | $1.0B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Immunome Inc. (IMNM) receives a "Reduce" rating with a composite score of 42.6/100. It ranks #3173 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IMNM.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 25 | 8 | +17ALPHA |
| MOMENTUM | 84 | 90 | -6DRAG |
| VALUATION | 27 | 16 | +11ALPHA |
| INVESTMENT | 36 | 63 | -27DRAG |
| STABILITY | 41 | 31 | +10ALPHA |
| SHORT INT | 24 | 10 | +14ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -71.8% (sector -1.9%)
GM N/A vs sector 44%, OM -1473% vs sector 3%
Capital turnover N/A
Rev growth -100%, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Immunome Inc. (IMNM) as a Reduce with a composite score of 42.6/100 at a current price of $22.12. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Immunome Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 42.6/100 places it at rank #3173 in our full universe.
The near-term outlook is constructive, with revenue growing at -100% and momentum in the 84th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
High
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Immunome Inc. represents a reduce based on multi-factor quantitative performance.
Immunome Inc. receives a Reduce rating from our analysis, with a composite score of 42.6/100 and 2 out of 5 stars, ranking #3173 out of 7,333 stocks. IMNM's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
IMNM's quality score of 25/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -71.8% (sector avg: -1.9%), net margins of -1374.2% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
IMNM registers a value score of just 27/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 8.99x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Immunome Inc.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 6.7% and a return on assets of -63.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
IMNM shows strong momentum characteristics with a score of 84/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at -100.0% year-over-year, while a beta of 1.45 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
IMNM's stability score of 41/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.45 and a debt-to-equity ratio of 13.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Immunome Inc.'s short interest score of 24/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.45), elevated leverage (D/E: 13.00x), small-cap liquidity risk. At $1.0B (small-cap), IMNM carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Immunome Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3173 of 7,333 overall (57th percentile). Key comparisons include ROE of -71.8% trailing the -1.9% sector median and operating margins of -1473.1% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IMNM currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (24) would have the largest impact on the composite score.
ROE 3681% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 58789% BELOW SECTOR MEDIAN
Debt/Equity 6090% ABOVE SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the “buy the rumor, sell the news” cliche came in fast and strong, quickly turning the rally into ... Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immunome (NASDAQ:IMNM) CEO and Chairman Clay Siegall outlined the company’s approach to building an oncology-focused pipeline and discussed recent clinical and regulatory milestones during a conversation with Guggenheim Senior Biotech Analyst Michael Schmidt. Pipeline strategy: targeted oncology fo
Key Insights Significantly high institutional ownership implies Immunome's stock price is sensitive to their trading...
H.C. Wainwright has initiated analyst coverage on Immunome, focusing on its oncology pipeline and overall positioning. The coverage launch brings additional attention to Immunome’s approach to cancer therapeutics and its progress as a NasdaqCM:IMNM listed company. Immunome, trading on NasdaqCM:IMNM, last closed at $22.425, with a 1 year return of 115.0% and a 3 year return that is roughly 4x. Over the past 30 days, the stock shows an 11.3% return, while the 7 day return reflects a 6.6%...